OMX Ventures
Venture capitalLincolnshire · Seed–Series A · 10 people tracked
Find your way into OMX Ventures
4,362 people in our graph share verified history with the OMX Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
OMX Ventures takes a technology-first, first-principles approach, prioritizing groundbreaking solutions over established executive rosters. Leveraging a deep network of advisors, the firm seeks disruptive opportunities that others overlook and supports founders with focused research and valuable networks. It emphasizes deep technical and intellectual property expertise, working hands-on with founders to hit milestones, establish strong IP, and attract follow-on capital. The firm's supportive ecosystem is geared toward helping biological solutions grow into scalable companies.
Source: firm website, verified Sep 15, 2026.
Team · 10 people
from the firm's website & public directories
What they invest in
from 30 of 38 portfolio companiesBiotech ×28Deep Tech ×16Healthtech ×13Medical Devices ×11AI & Machine Learning ×9Digital Health ×5Hardware ×3AgTech ×1
HQs:United States×15United Kingdom×2
Who they back
founder profiles across 18 portfolio companiesFounding team size:solo founder×92 founders×53 founders×34+ founders×1
Where their founders studiedfrom 21 founders with education data
Massachusetts Institute of Technology ×6Stanford University ×3Princeton University ×2Stanford University School of Medicine ×2University of California, Berkeley ×2University of California, San Francisco ×2
What their founders studiedfrom 22 founders with field-of-study data
Engineering ×8Life Sciences ×8Chemistry ×5Computer Science ×3Business & Management ×2Mathematics & Statistics ×2Physics ×2
Accelerator rootsportfolio companies that came through a program
22 founders hold a PhD (of 22 with degree data)
Investments · 38 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 42022 · 22021 · 12020 · 12019 · 22018 · 113 dated
10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers.
BiotechDeep TechHardwareHealthtechPleasanton, US
Serge Saxonov(Founder)inBen Hindson(Founder)inBrad Crutchfield(Chief Commercial Officer)Jean Philibert(Chief People Officer)Eric S Whitaker(General Counsel)inJustin McAnear(Chief Financial Officer)
Co-investorsFoothill VenturesForesite CapitalKhosla VenturesPaladin Capital GroupSoftBank Vision FundVenrock+4 more
Compass Pathways develops novel treatments for mental health conditions, with a focus on psychedelic-assisted therapies supported by rigorous clinical research.
BiotechDigital HealthHealthtechMedical DevicesMental Health
Kabir Nath(CEO)
Co-investorsAble PartnersAisling CapitalCatalio Capital Management, LPNoeticVivo CapitalJam Fund
Ginkgo Bioworks builds autonomous labs that accelerate bioengineering for applications in pharmaceutical, agricultural, and industrial biotechnology.
AgTechAI & Machine LearningBiotechDeep TechHealthtechRoboticsBoston, US
Jason Kelly(Co-founder & CEO)inReshma Shetty(Co-founder, President & Chief Operations Officer)inBarry Canton(Foundry Technology Strategy & Direction)inAustin Che(Strategic Partnerships & Investments)inTom Knight(Founder, Ginkgo Fellow)
BoardReshma Sohoni
Co-investors11.2 CapitalAllen Institute for AI (AI2) IncubatorB3 HoldingCannage CapitalCool Climate CollectiveDCVC (Data Collective)+21 more
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily M. Leproust(Chief Executive Officer and Chair of the Board)inPatrick Finn(President and Chief Operating Officer)inAdam Laponis(Chief Financial Officer)in
Co-investors+ND Capital3E Bioventures CapitalARCH Venture PartnersAsset Management CompanyBay City CapitalBlack Opal Ventures+8 more
Switchback Systems develops a benchtop DNA synthesis platform that combines onboard oligonucleotide synthesis and gene assembly, aimed at putting synthetic biology tools directly in scientists' hands.
BiotechDeep TechHardwareSan Francisco Bay Area, US
Mary Noe(Executive Officer, Director)in
BoardTimothy Richardson(Director)Paul Conley(Director)inA Craig Asher(Director)
Co-investorsAhren Innovation CapitalGENERAL INCEPTIONVertical Venture Partners
Aperiam Bio uses computer-vision algorithms to identify "hyperfolding" protein variants with improved expression, solubility, and stability, aiming for order-of-magnitude gains in protein performance.
AI & Machine LearningBiotechDeep TechAustin, US
Austin Cole(CEO & Founder)Guillaume Cottarel(Head of Program)inRussell Durrett(Chief Business Officer)
Co-investorsCivilization Ventures Management, LlcAxial VCKdT Ventures
Cellsonics provides cell dissociation technology for research scientists using acoustic waveforms to isolate cells from tissue with higher biological relevance than conventional methods.
BiotechDeep TechHardwareMedical Devices
Co-investorsVertical Venture PartnersWavemaker Three-Sixty Health
Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured.
BiotechDeep TechNew Materials
Jason Chin(Professor)
Co-investors+ND CapitalAmadeus Capital PartnersFine Structures VenturesGENERAL INCEPTIONLongeVCPaladin Capital Group+3 more
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesCasa Verde CapitalNoeticPsyMed VenturesRA CapitalVertical Venture Partners+6 more
Epana Bio develops therapies for autoimmune diseases by leveraging genomics and AI to identify and target cellular origins of disease, with a focus on precision medicine for patient populations.
AI & Machine LearningBiotechDigital Health
Co-investorsBreakout LabsBreakout VenturesHAWKTAILHummingbird VenturesKdT VenturesRefactor Capital
Finch Therapeutics is a life sciences company focused on the development and protection of drug-related intellectual property and therapeutics within the biotechnology and pharmaceutical industry.
BiotechHealthtechMedical DevicesSomerville, US
Mark Smith(Executive Officer, Director)inMatt Blischak(Chief Executive Officer)inR. J. Price(Director)Jeffery A. Smisek(Director)Andrew Mulderry(Director)James Burgess(Director)
Co-investorsB3 HoldingOctave Ventures LlcOCV PartnersShumway CapitalHumboldt
Freya Biosciences develops innovative therapies targeting immune-mediated diseases that affect women.
BiotechFemTechHealthtech
Colleen Acosta, PhD(CEO, Co-Founder)Johan van Hylckama Vlieg, PhD(CSO, Co-Founder)
Co-investorsAngelini VenturesIndaco Venture PartnersSofinnova PartnersBill & Melinda Gates Foundation
General Inception is an operational support and company building firm that handles day-to-day planning and execution for building companies, with a focus on life science tools and diagnostics.
Deep TechHealthtechMedical Devices
Co-investorsPaladin Capital GroupGenoa VenturesNorthpond VenturesVertical Venture Partners
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Daniel Estandian(Founder)inEd Boyden(Founder)Josh Yang(Founder)in
BoardCraig Asher(Director)inJimmy Yun(Director)in
Co-investorsArtis VenturesBlack FlagCivilization Ventures Management, LlcFoundersX VenturesHarpoon VenturesLongeVC+5 more
BiotechBoulder, US
Michael Graige(Executive Officer)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)
BoardRoger Wyse(Director)inBryan Roberts(Director)in
Co-investorsForesite CapitaliGlobe PartnersKorysOak HC/FTPaladin Capital GroupSpruce Capital Partners+3 more
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investors+ND CapitalIllumina VenturesLongwall Venture Partners LLPM VenturesARCH Venture Partners
Matterworks builds foundation models (its Large Spectral Model, delivered via the cloud-based Pyxis platform) that analyze biochemical omics and mass spectrometry data to make predictions for life science R&D.
AI & Machine LearningBiotechHealthtech
Jack Geremia, PhD(Founder)in
Co-investorsDYDX CapitalGermin8 Ventures
Overt Bio develops cell therapies that link genes to immune functions using genome-scale discovery platforms.
AI & Machine LearningBiotechMedical DevicesNew York, US
Dr. Legut(Co-Founder and CEO)Dr. Sanjana(Co-Founder)Mateusz Legut(Executive Officer, Director)Neville Sanjana(Director)Mat Legut(Founder)in
BoardVasudev Bailey(Director)in
Co-investorsArtis VenturesCivilization Ventures Management, LlcFusionHAWKTAILWingAlexandria+1 more
Reaxbio develops a chemoproteomics platform that identifies and targets novel protein sites for drug discovery across disease-relevant biological contexts.
AI & Machine LearningBiotechDeep Tech
Jeff Montgomery(Founder)in
Co-investorsPortal Innovations
Replay develops gene therapies for patients with rare genetic diseases.
BiotechHealthtechLongevity
Lachlan MacKinnon(CEO and Founder)Adrian Woolfson(Founder)Robert Coffin(Executive Chairman)Maria Castner-Miller(General Counsel)inRenata Martin(VP & Head of Gene Therapy)inSaurabh Sharma(VP & Head of CMC)
Co-investorsArtis VenturesSolari CapitalAxial VC
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)inAashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)inRoland Gendron(Chief Business Officer)inMichelle Zhang(Chief Scientific Officer)in
BoardVineeta Agarwala(Director)in
Co-investorsRA CapitalAndreessen HorowitzMagnetic VenturesAxial VCGV (Google Ventures)LoLa Capital Partners+1 more
Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples.
BiotechDeep TechMedical DevicesSanta Monica, US
Geoff Smith(Founder & CEO)inJason Betley(Chief Product Officer)in
Co-investors+ND CapitalARCH Venture Partners
Tagomics develops multimodal technologies for precision medicine and next-generation diagnostics.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, GB
Dr Jack Kennefick(Co-founder, Director & Chief Executive Officer)Dr Robert Neely(Co-founder, Director & Chief Scientific Officer)
Co-investorsCalculus Capital Ltd.Illumina VenturesIQ CapitalCalculusMEIF Proof-of-Concept & Early Stage FundMercia Ventures+1 more
.jpeg){kind=logo}
Tasso develops diagnostic testing devices and platforms for home use, enabling patients to perform health monitoring and inform clinical decisions outside traditional healthcare settings.
Digital HealthHealthtechMedical DevicesSeattle, US
Ben Casavant(Co-Founder and Chief Executive Officer)inErwin Berthier(Co-Founder and Chief Technology Officer)inAlan Levy(Director)
BoardElizabeth Hambrecht(Director)Paul Conley(Director)in
Co-investorsForesite CapitalJ2 VenturesRA CapitalTechstarsVenture Capital Investment ManagementVertical Venture Partners
Tessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases.
BiotechDigital HealthMedical Devices
Geoff von Maltzahn(Founder)inJoseph Romanelli(CEO)
Co-investorsArtis VenturesFlagship PioneeringMarch Capital PartnersSoftBank Vision FundSolari CapitalToba Capital+4 more
SyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists.
AI & Machine LearningBiotechDeep Tech
Maria Soloveychik(PhD)in
Co-investorsNorth South VenturesThe Column Group8VC
Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies.
BiotechDeep TechHealthtech
Gert Kiss(Co-founder & CEO)inAlexander Bridges(Co-founder, CSO, VP Chemistry)Jeffrey Ohren(Co-founder, VP Biology)inMihail Obrocea(Head of Development)Robert Sons(Head of Operations)
Co-investorsArtis VenturesBoxOne Ventures
VedaBio develops a molecular detection platform using CRISPR technology that enables rapid, accurate detection of multiple biological targets without the need for amplification.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Diego, US
Anurup Ganguli(Founder)inFred(President and CEO)Frédéric Sweeney(President and Chief Executive Officer)inMaurice Exner(Chief Operating Officer)in
Co-investorsIllinois VenturesY Combinator
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
1859CompassFinchMatterworksSestinaSyntheXTARATARA BiosystemsType6Xerispharma
Exits · 4
4 IPOs10x Genomics 1-colorNASDAQ: TXGCompass PathwaysNASDAQ: CMPSGinkgo BioworksNYSE: DNATwist BioscienceNASDAQ: TWST
Portfolio news
latest coverage across their companiesGinkgo Bioworks · ca.investing.com · Jul 17, 2026
Lightcast · kb.lightcast.io · Jul 2, 2026
Tessera · erp.today · Jun 26, 2026
Stipple Bio · bioxconomy.com · Apr 10, 2026
Syndex · cambridgebiocapital.substack.com · Mar 9, 2026
Inscripta · chiefhealthcareexecutive.com · Jan 8, 2026
Constructive Bio · nature.com · Oct 20, 2025
Frequently asked questions
- How many investments has OMX Ventures made?
- OMX Ventures has 38 tracked investments, 4 of which have exited, including 3 dated in the last 24 months.
- What stage does OMX Ventures invest at?
- OMX Ventures invests at the Seed, Series A stages.
- What sectors does OMX Ventures focus on?
- OMX Ventures focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is OMX Ventures located?
- OMX Ventures is headquartered in Lincolnshire, US.
- Does OMX Ventures lead rounds?
- OMX Ventures typically participates in rounds rather than leading them.
- Who does OMX Ventures co-invest with?
- OMX Ventures most often shares deals with Artis Ventures, Vertical Venture Partners, RA Capital, among 88 tracked co-investors.
Co-investors · 1
Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.
Firms observed investing alongside OMX Ventures, from public investor directories. Shared companies are the overlap with OMX Ventures's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.